Primary Care

Obesity Medicine

Questions discussed in this category

Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?

1 Answer available

How do you discuss the role (if there is any) of frequently weighing yourself at home for patients who desire weight loss?

Is there a role, or do you find it largely drives the fixation of health being based on the number on the scale?

3 Answers available

What strategies do you recommend to address the negative self-talk/internalized bias that patients carry about their own weight?

Shifting away from a "goal weight" or BMI to a healthy lifestyle mindset.

1 Answer available

Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?

3 Answers available

How would you manage a patient taking a GLP-1 agonist for weight loss who continues to have symptoms (i.e., nausea, vomiting) related to reduced GI motility despite dose adjustments?

Would you anticipate a different side effect profile from a different GLP-1 agonist?

5 Answers available

How do you counsel patients on GLP-1 agonists for weight loss who wish to space out their medication or take a "drug holiday" to temporarily increase their appetite?

For example, if someone has an upcoming vacation or family gathering, is it okay to temporarily stop their medication to increase their appetite?

1 Answer available

How do you decide whether to reinitiate a GLP-1 agonist after a patient has experienced acute pancreatitis while on this therapy?

1 Answer available

When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?

1 Answer available

Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?

1 Answer available

Do you routinely check vitamin K levels in post-bariatric surgery patients?

There seems to be little guidance on vitamin replacement in these patients. Vitamin K level < 50 yet PT/INR is normal. Is the vitamin K assay usefu...

1 Answer available

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?

Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...

1 Answer available

What work up do you recommend in post bariatric surgery patients who are slowly gaining back the weight despite no changes in diet?

1 Answer available

How do you approach the use of GLP-1 receptor agonists for the management of patients with metabolically healthy obesity?

1 Answer available

Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?

3 Answers available

What strategies do you employ for adjusting the dosage of levothyroxine in hypothyroid patients who experience significant weight loss or are initiated on GLP-1 receptor agonists?

How often do you recommend monitoring thyroid function tests in these situations?

1 Answer available

How do you counsel patients on the use of compounded weight loss medications?

3 Answers available

Should weight loss medications be used in women who are gaining excessive weight during pregnancy?

1 Answer available

Which patient population would benefit most from cellulose and citric acid (Plenity) therapy for weight loss?

1 Answer available

Is intermittent fasting effective for weight loss?

3 Answers available

Should metformin be used in women with PCOS for weight loss?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2022 Apr 21

Calorie Restriction with or without Time-Restricted Eating in Weight Loss.

BMC endocrine disorders, 2024 Nov 18

Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.

International urology and nephrology, 2024 Nov 04

Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.

Cancers, 2024 Sep 22

Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.

Frontiers in pharmacology, 2023 Mar 16

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.

Nutrition & diabetes, 2019 Nov 04

Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors.

Diabetes, obesity & metabolism, 2019 Aug 19

Double diabetes: A distinct high-risk group?

BMC endocrine disorders, 2021 Sep 16

The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study.

Diabetes care, 2021 May 05

High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.

Gastroenterology, 2021 Oct 27

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2019 Jun 05

Vitamin K-what is known regarding bariatric surgery patients: a systematic review.

Nutrients, 2016 Jan 02

Concepts and Controversies in Evaluating Vitamin K Status in Population-Based Studies.

The New England journal of medicine, 2015-07-02

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Annals of translational medicine, 2021 Sep

Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.

The New England journal of medicine, 2025 May 11

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

Related Topics in Primary Care